SCHEMBL14018317

SCHEMBL14018317

Cc1ccc(N(c2ccc(-c3ccc(N(c4ccc(N(c5ccccc5)c5ccccc5)cc4)c4ccc(C)c5ccccc45)cc3)cc2)c2ccc(N(c3ccccc3)c3ccccc3)cc2)c2ccccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.45
ALDH1A1 P00352 4/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
KDM4E B2RXH2 2/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2D6 P10635 2/20 0.38
MAPT P10636 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
TDP1 Q9NUW8 1/20 0.38
CYP2A6 P11509 2/20 0.35
APP P05067 3/20 0.35
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
MEN1 O00255 1/20 0.33
CRHBP P24387 1/20 0.33
KMT2A Q03164 1/20 0.33
ATM Q13315 1/20 0.33
CRHR2 Q13324 1/20 0.33
TLR9 Q9NR96 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1455714 0.98 CYP1A2 (0.46) CYP1A2ALDH1A1L3MBTL1KDM4ECYP3A4
SCHEMBL12394113 0.91 CYP1A2 (0.54) CYP1A2ALDH1A1L3MBTL1KDM4ECYP3A4
SCHEMBL14016106 0.91 CYP1A2 (0.39) CYP1A2ALDH1A1L3MBTL1KDM4ECYP3A4
SCHEMBL14382391 0.90 CYP1A2 (0.45) CYP1A2ALDH1A1KDM4EMAPTCYP2C19
SCHEMBL18069072 0.89 CYP2A6 (0.42) CYP1A2ALDH1A1L3MBTL1CYP3A4CYP2D6
SCHEMBL18069067 0.89 CYP2A6 (0.42) CYP1A2ALDH1A1L3MBTL1CYP3A4CYP2D6
SCHEMBL13854496 0.89 ALDH1A1 (0.46) CYP1A2ALDH1A1L3MBTL1KDM4ECYP3A4
SCHEMBL13868380 0.88 CYP1A2 (0.46) CYP1A2ALDH1A1L3MBTL1KDM4ECYP3A4
SCHEMBL10053533 0.87 CYP1A2 (0.54) CYP1A2ALDH1A1L3MBTL1KDM4ECYP3A4
SCHEMBL7477408 0.87 ALDH1A1 (0.43) CYP1A2ALDH1A1L3MBTL1KDM4ECYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080241591-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND PHENYLENEDIAMINE DERIVATIVE IDEMITSU KOSAN CO., LTD. (JP) 2008-10-02 US disclosed
US-20080241591-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND PHENYLENEDIAMINE DERIVATIVE IDEMITSU KOSAN CO., LTD. (JP) 2008-10-02 US disclosed
US-7399537-B2 Organic electroluminescence device and phenylenediamine derivative IDEMITSU KOSAN CO., LTD. (JP) 2008-07-15 US disclosed
US-7399537-B2 Organic electroluminescence device and phenylenediamine derivative IDEMITSU KOSAN CO., LTD. (JP) 2008-07-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080241591-A1 ORGANIC ELECTROLUMINESCENCE DEVICE AND PHENYLENEDIAMINE DERIVATIVE MAL2, L1CAM, EPCAM CYP1A2 1348/4885ALDH1A1 734/4885L3MBTL1 605/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.